MARKET
Sysmex Corporation opens new office in Mumbai Starts its direct operations in India in the field of coagulation and biochemistry SYSMEX CORPORATION recently started its direct operations in India in the field of coagulation and biochemistry. This was announced by Anil Prabhakaran, MD, Sysmex India. A new office was inaugurated recently at Kanjur Marg, Mumbai at the hands of Hisashi Ietsugu, President, Sysmex Corporation, in the presence of Kazuya Obe, Senior Executive Officer, Sysmex Corporation, Iwane Matsui, Executive Officer, Sysmex Corporations, Frank Buescher, President and CEO, Sysmex Asia Pacific. A host of distinguished doctors and luminaries from the IVD industry such as Dr Velumani, CEO, Thyrocare labs, Dr Avinash Phadke, President SRL Diagnostics and Dr Phadke’s lab, Dr Shanaz Khodaiji, Consultant, Dept. of Lab Medicine, PD Hinduja Hospital, Dr Sushil Shah, Founder and Chairman, Metropolis Healthcare, and many more prominent dignitaries graced the occasion. The entire range of Sysmex coagulation analysers cater to small-mid-large sized labs from semi-automated single test analyser, with the newly launched CA-101 and CA-104, to the fully automated CA-600 series and the top-of the line CS-2000 series, all with varying throughputs, to cater to specific needs and offering best-in-class technology to perform clotting, chromogenic and immunological assays. The haemostasis reagent range covers routine and specialised coagulation testing for bleeding, thrombophilia and platelet function disorders in order to help the clinician make accurate and timely diagnosis. The biochemistry instrument portfolio includes the BX3010 and BX-4000 (table-top) and the JCA-BM6010/C (Floor model) automated chemistry analyser. They have superior performance efficiency to help
From L to R: Iwane Matsui, Executive Officer, Sysmex Corporation, Dr A Velumani, CEO, Thyrocare labs, Anil Prabhakaran, Managing Director, Sysmex India, Yoshimitu Kawata, Chief Consul at Consulate General of Japan, Mumbai, Kazuya Obe, Senior Executive Officer, Sysmex Corporation, Hisashi Ietsugu-President Sysmex Corporation, Suresh Vazirani-Chairman and Managing Director,Transasia Biomedicals, Frank Buescher, President and CEO, Sysmex Asia Pacific, Atsuhito Koyama, Chairman,Sysmex India
From L to R: Iwane Matsui,Executive Officer, Sysmex Corporation, Hisashi Ietsugu-President Sysmex Corporation, Frank Buescher, President and CEO, Sysmex Asia Pacific, Yoshimitu Kawata, Chief Consul at Consulate General of Japan, Mumbai during the ribbon cutting ceremony
labs achieve faster turnaround time with accuracy. The test menu is varied and all-encompassing to suit the individual needs of the laboratory. Reaching out to customers through a global network of operations, Sysmex India promises to exceed their expectations
by offering quality products and fine-tuned after sales support, real time monitoring of customer instruments through online support service for providing remote maintenance and quality control monitoring, and sharing the latest academic information and trends by organis-
ing seminars and symposiums. The corporate office is in Mumbai, with representatives in New Delhi, Bangalore, Chennai, Kochi, and Kolkata and shortly in Ahmedabad, Hyderabad, Pune and all the major cities in India. EH News Bureau
Strand Life Sciences MSMF partners BANGALORE BASED Strand Life Sciences entered into a partnership with the Mazumdar-Shaw Medical Foundation (MSMF) to set up the Strand at Mazumdar-Shaw (SAMS) translational lab in the Mazumdar-Shaw Centre for Translational Research (MSCTR) located at Bangalore. “With evolving healthcare systems, it is imperative that we are constantly innovating and developing capabilities that will provide personalised treatment and quality care to the people of India. We believe this collaboration will help us foster innovation and encourage indepth research in the genomics space and thereby provide better care for patients with cancer and other genetic diseases,” said Dr Kiran MazumdarShaw, CMD, Biocon. Strand will offer comprehensive genomic testing for cancer and other germline/hereditary conditions at highly affordable costs. In addition, the collaboration will also entail promoting research in the field of genomics, conducting medical and nonmedical programmes, seminars and talks shows, assisting clinicians and scientists in performing quality research, and towards making genomics research resources and data available to scientists. Dr Vijay Chandru, Chairman & CEO, Strand Life Sciences said, “The Mazumdar-Shaw Medical Foundation has shown great foresight and magnanimity in helping us work towards the goal of providing the leading edge of genomic medicine at affordable prices in India and elsewhere. This collaboration provides Strand with an opportunity to conduct and promote in-depth research in the field of genomic sequencing based diagnostics. EH News Bureau
EXPRESS HEALTHCARE
15
May 2014